Acorda Therapeutics Cdt Stock
Your prediction
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
| Ardelyx Inc. | -1.850% | 26.879% | 14.302% | 4.896% | 23.005% | 108.094% | 5.740% |
| Evolus Inc | -0.830% | -2.823% | -15.439% | -48.449% | -11.560% | -38.599% | 15.838% |
| Champions Oncology Inc | - | 1.818% | 8.738% | 17.647% | -3.448% | 40.704% | -36.364% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat